Home / Health / UK Approves Groundbreaking Ovarian Cancer Drug
UK Approves Groundbreaking Ovarian Cancer Drug
4 Jun
Summary
- NICE recommends AbbVie's Elahere for hard-to-treat ovarian cancer.
- Drug available via confidential NHS agreement, widening treatment access.
- Around 270 patients eligible in the first year for the new therapy.
The UK's health watchdog, NICE, has recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer.
This groundbreaking decision makes Elahere accessible to patients through a confidential commercial agreement with the NHS. This follows NICE's revision of its value appraisal framework, a change intended to broaden access to treatments previously deemed too costly.
Critically ill patients whose cancer no longer responds to standard chemotherapy will now be able to receive Elahere via the NHS. Previously, access was restricted to clinical trials, private care, or compassionate use. Approximately 270 patients are anticipated to be eligible in the first year, with numbers growing to about 420 by year three.
Elahere, an antibody-drug conjugate, is designed for precise targeting of cancer cells. It is administered every three weeks and reportedly has a more manageable side-effect profile compared to traditional chemotherapy. This recommendation marks the first new choice for ovarian cancer patients at a critical stage in over two decades.
